What Can the Pharma Industry Learn from Merck’s New Antiviral?

 

Merck is one of the first pharmaceutical companies to submit an antiviral candidate to the FDA for approval, signaling the beginning of a new phase of mass production of COVID treatment drugs. For Merck’s oral antiviral, molnupiravir, its optimistic success can be largely credited to its federal funding. Work on the related compound was active at Emory University as far back as 2004, with millions

With that kind of federal investment, and Operation Warp Speed validating the role of the federal government in supporting critical biomedical development, we wanted to know: can the industry expect any further involvement, financial or regulatory, from the federal government around COVID treatments? Plus, as Operation Warp Speed accelerated the COVID vaccine research timeline, are there more sustainable ways to bring this level of turnaround to other parts of the pharmaceutical pipeline without lags in treatment quality or oversight?

MarketScale sourced Dr. Kishor M. Wasan, Chief Medical and Scientific Officer at Skymount Medical, for his perspective, pulling from his active research around drug production and AI. Scroll down for his various insights!

1. Do the Successes of Operation Warp Speed Validate the Support of the Federal Government?

 

2. How LSU Designed a Model to Speed Up the Evaluation of Drug Candidates

 

3. How the Pharmaceutical Pipeline can Balance Speed and Quality

 

Follow us on social media for the latest updates in B2B!

Image

Latest

healthcare operations
Healthcare Operations Improve with AI That Unites Data, Automation, and Ethics
June 18, 2025

Generative AI has captured the public imagination, but its most transformative use cases may lie far from flashy consumer tools. In healthcare operations, where complexity, inefficiency, and fragmentation remain persistent challenges, AI is now driving measurable improvements. Research suggests AI-enabled healthcare systems could cut administrative costs by up to $360 billion in the U.S. alone….

Read More
Clinical CBD
Verified, Tested, Trusted: How Corganics Ensures THC-Free Confidence in Clinical CBD
June 18, 2025

Corganics is redefining standards in clinical cannabinoid care with THC-free, medical-grade CBD products developed for use exclusively by healthcare professionals. Backed by Advanced Lipid Technology, FDA-registered manufacturing, and rigorous third-party testing, Corganics offers a level of trust and transparency rare in the CBD space. In a conversation with Reggie Gatewood, President of Corganics, Brooke Williams,…

Read More
Clinical CBD Drops
Corganics’ Clinical CBD Drops: Elevating Sleep and Patient Care at Beautiphi
June 18, 2025

Corganics’ Clinical CBD Drops—THC-free, medical-grade, and developed with Advanced Lipid Technology—are designed for healthcare professionals seeking a trusted, science-backed cannabinoid solution for their patients. Manufactured in an FDA-registered facility and third-party lab-tested, these drops are a cornerstone of Corganics’ clinical approach. At Beautiphi Aesthetic Boutique, founder Kelly Hermans, CRNA, has integrated the drops into patient…

Read More
leadership confidence
Liz Atlee on Leadership Confidence and Letting Go of Doubt – Raise Your Hand Anyway, Even When You Feel Unsure
June 18, 2025

In this episode of Professional Quotient: Conversations That Build Equity, host Jason Winningham welcomes legal powerhouse and mentor extraordinaire Liz Atlee for an honest conversation about leadership confidence, imposter syndrome, transparency in leadership, and the importance of simply raising your hand—even when you feel unsure. Liz brings a wealth of experience navigating high-stakes legal…

Read More